XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

US Medicare says Part D and Advantage premiums will fall in 2025



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US Medicare says Part D and Advantage premiums will fall in 2025</title></head><body>

By Ahmed Aboulenein

WASHINGTON, Sept 27 (Reuters) -Average premiums and benefits for Medicare's prescription drug program and private Medicare plans are projected to remain stable in 2025 with premiums slightly declining, the Centers for Medicare and Medicaid Services said on Friday.


WHY IT'S IMPORTANT

The premiums are of interest to consumers enrolled in Medicare Advantage plans run by private insurers who are then paid by the government, and the health plans themselves, who set premiums and benefits based on the reimbursement rates.

The government has been trying bring down MA prices to the level of original Medicare, the government health plan for those age 65 and older.

Private health insurers had argued cutting their rates would limit what benefits they offer, but the government's projections on Friday showed they remain stable. Shares of health insurers had fallen between 6% and 12% in April when the rates were announced.


CONTEXT

Medicare is the U.S. government's health insurance program for people over the age of 65 and the disabled.

Medicare Advantage plans are offered by private insurers who are paid a set rate by the government to manage healthcare for Medicare beneficiaries who want extra benefits not offered in regular Medicare coverage.

Medicare also contains an optional prescription drug coverage program known as Part D.

The Centers for Medicare and Medicaid Services, which runs Medicare, announced in April its final 2025 rates for MA payments, which included a 0.2% cut.

The cut is part of a three-year plan to decrease payments to MA plans as part of an effort the government says will bring them more in line with original Medicare.


BY THE NUMBERS

Medicare Advantage plan enrollment will grow to 35.7 million people in 2025, or 51% of all Medicare beneficiaries, up from 50% in 2024.

Average MA monthly premiums are projected to fall by $1.23 from $18.23 in 2024 to $17 in 2025.

Almost 60% of beneficiaries will have zero-dollar premiums in 2025 and 83% will have the same premiums or lower if they stay with their current plan, including 20% who will see premiums fall.

Average Part D premiums are projected to fall by $7.45 in 2025 to $46.50, down from $53.95 in 2024.



Reporting by Ahmed Aboulenein
Editing by Bill Berkrot

</body></html>

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.